E. Jager(1), V. H.J. van der Velden(2), J. G. te Marvelde(2), R. B. Walter(3,4), Z. Agur(1,6), V. Vainstein(1,5). Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based pharmacokinetic model for treatment strategy improvement and prediction of individual responses.
|
Ron J Keizer (1), Anubha Gupta (2), Mendel Jansen (2), Jantien Wanders (2), Jos H Beijnen (1,4), Jan HM Schellens (3), Mats O Karlsson (5), Alwin DR Huitema (1) Modeling of hypertension in response to anti-angiogenic therapy
|
WS Denney (1), Y Hang (2), MF Dockendorf (1), C-C Li (1), SR Eid (3), R Valesky (1), T Laethem (5), P Van Hoydonck (5), I DeLepeleire (5), JNJM de Hoon (6), M Crutchlow (4), R Blanchard (4) Modeling and Simulation for Determination of the Therapeutic Window of MK-2295: a TRPV1 Antagonist
|
David Ternant (1,2), Emilie Hénin (1), Guillaume Cartron (3), Michel Tod (1), Gilles Paintaud (1), Pascal Girard (1) Model-based optimization of rituximab dosing regimen in follicular non-Hogdkin lymphoma
|
F.Stringer (1), B.Ploeger (2,3), J. de Jongh (2,3), G.Scott (1), R Urquart (5), A.Karim (4) and M. Danhof (2,3) Genotyped versus phenotyped dosing to account for UGT polymorphism of the novel PPAR agonist sipoglitazar
|
W. de Winter(1), S. Rossenu (1), A. Dunne (1), A. Vermeulen (1) Integrating a Model for Weight Change into the Mechanism-Based Model for Type 2 Diabetes
|
Robert M. Kalicki, Rocío Lledó-García, Mats O. Karlsson Modeling of Red Blood Cell (RBC) Lifespan (LS) in a Hematologically Normal Population
|